HQ: Nanaimo, British Columbia
Facilities: Nanaimo, BC. Another opening in Enniskillen, Ontario
Symbol: TLRY (OTC), 2HQF (Franfurt)
Licenses: Cultivation, Production, Sales. Applying for Dealer’s license (for export)
CEO: Brendan Kennedy
Research, cultivation, processing, and distribution of medical cannabis internationally.
Market Cap: $6 billion
Enterprise Value: $4.7 billion
Size (mkt cap) within cannabis industry: 2 of 200+
Size among cultivators: 2 of about 40
# of employees: N/A
Secondary: Germany, the UK, Argentina, Australia, Chile, Croatia, Cyprus, the Czech Republic, New Zealand, South Africa.
Current production: exact figure not available. 100,000 kgs (912,000 sf) by end 2018.
Future production: Max potential is 400,000+ kgs
Direct sales: Yes, it has a large number of current patients
Should you invest in Tilray, Inc. TLRY (NASDAQ)? Recommendation: See Below
Vertically integrated: Yes, cultivation and distribution (not sure how much direct sales)
Horizontally diversified: Not much. Most focus is on cultivation. Some medical R&D,
Revenue rank among cultivators: 5th
Revenue growth (YoY): 97%
Net income per share: N/A
Total cost per gram: $6.38
Cost per gram rank in industry: N/A
CEO: Brendan Kennedy
CFO: Mark Castaneda
CMO: Adine Fabiani-Carter
Chief Revenue Officer: Edward Pastorius
Chief Science Officer: Josh Eades
Head of research: Dr. Catherine Jacobson
The company launched a new cannabis brand called CANACA™, celebrating Canadian roots and pride as the country becomes the world’s first G7 nation to federally legalize cannabis for adult-use.
Tilray signed an agreement with Sandoz Canada, a division of Novartis, to create and sell co-branded and co-developed non-combustible medical cannabis products.
Current share price: $65
Price to Sales: 213 (Tobacco industry = 5)
Price to Book: 137
EV / revenue: 167
EV / revenue rank in the industry: 2nd highest out of the top 20 cultivators (expensive)
The company completed its IPO in July selling 10.3 million shares of Class 2 Common Stock to the public for $17.00 per share. Just a month later, the stock now trades at US$62, a 360% rise. Tilray netted US$163.6 million on the IPO. Proceeds will go to build out cultivation capacity, repay debt, and for future acquisitions and working capital.
Prior to the IPO, it raised US$55 million of Series A funding from institutional investors.
All cannabis stocks present risks due to the relative newness of the company and market. The company is not yet producing real profits, only revenue. It remains to be seen whether Tilray will succeed in the competitive market to emerge as one of the successful cannabis companies in the coming year or two.
About Cannin: Cannabis and Hemp Investment Experts
Market analysts expect the cannabis and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in cannabis and hemp stocks is now! Are you looking to buy stock in hemp companies or cannabis companies? Interested in emerging penny pot stock companies? Looking for the best Canadian pot company to invest in? Cannin is your trusted resource for information about Cannabis and Hemp stock investment opportunities. Our global team of experts evaluates emerging cannabis stock investing opportunities. We aggregate hundreds of hours of research and distill it down to make it easy for our investors to understand. We provide tips on the best cannabis and hemp stock investments for 2020. We provide the latest hemp investment news and analysis. Visit our site for cannabis investing news and featured companies, sign up for the free Cannin Chronicle or get a free trial of our smart cannabis and hemp stock algorithm to take the guesswork out of profiting from this exciting industry. Predict the price of cannabis and hemp stocks hours in advance with our machine learning algorithm. Is it too late to invest in marijuana companies like Tilray? No! This is the perfect time.
Profit from the best Cannabis and Hemp stocks – we’ll show you how at cannin.com